Pharmaceutical firm Gilead Sciences has agreed to buy Kite Pharma, a company that has developed a gene therapy for treating cancers. The resulting CAR-T therapy, as it’s known, is one of several being developed by the likes of Novartis and Juno Therapeutics to treat cancer, and they all appear to show huge promise for curing the disease. Through the deal, Gilead will obtain rights to Kite's CAR-T therapy, a treatment for blood cancers such as lymphoma. The therapy reprogrammes the DNA within individuals' immune cells to attack the disease. In an interview with Reuters,
Pharmaceutical firm Gilead Sciences has agreed to buy Kite Pharma, a company that has developed a gene therapy for treating cancers. Through the deal, Gilead will obtain rights to Kite's CAR-T therapy, a treatment for blood cancers such as lymphoma. The therapy reprogrammes the DNA within individuals' immune cells to attack the disease. In an interview with Reuters,